JP4383855B2 - パイエル板および／またはｍ細胞を標的とするリガンド - Google Patents

パイエル板および／またはｍ細胞を標的とするリガンド Download PDF

Info

Publication number
JP4383855B2
JP4383855B2 JP2003510683A JP2003510683A JP4383855B2 JP 4383855 B2 JP4383855 B2 JP 4383855B2 JP 2003510683 A JP2003510683 A JP 2003510683A JP 2003510683 A JP2003510683 A JP 2003510683A JP 4383855 B2 JP4383855 B2 JP 4383855B2
Authority
JP
Japan
Prior art keywords
seq
peptide
synthetic polypeptide
amino acid
purified synthetic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2003510683A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005503782A5 (https=
JP2005503782A (ja
Inventor
オマホニー、ダニエル
ランブキン、イメルダ
ヒギンズ、リサ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merrion Research Ill Ltd
Original Assignee
Merrion Research Ill Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merrion Research Ill Ltd filed Critical Merrion Research Ill Ltd
Publication of JP2005503782A publication Critical patent/JP2005503782A/ja
Publication of JP2005503782A5 publication Critical patent/JP2005503782A5/ja
Application granted granted Critical
Publication of JP4383855B2 publication Critical patent/JP4383855B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4725—Proteoglycans, e.g. aggreccan
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/02—Linear peptides containing at least one abnormal peptide link
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Compounds Of Unknown Constitution (AREA)
JP2003510683A 2001-07-02 2002-06-28 パイエル板および／またはｍ細胞を標的とするリガンド Expired - Fee Related JP4383855B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US30259101P 2001-07-02 2001-07-02
PCT/IB2002/003401 WO2003004517A2 (en) 2001-07-02 2002-06-28 Peyers's patch and/or m-celle targeting ligands

Publications (3)

Publication Number Publication Date
JP2005503782A JP2005503782A (ja) 2005-02-10
JP2005503782A5 JP2005503782A5 (https=) 2008-12-18
JP4383855B2 true JP4383855B2 (ja) 2009-12-16

Family

ID=23168408

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003510683A Expired - Fee Related JP4383855B2 (ja) 2001-07-02 2002-06-28 パイエル板および／またはｍ細胞を標的とするリガンド

Country Status (8)

Country Link
US (3) US6916789B2 (https=)
EP (1) EP1432729B1 (https=)
JP (1) JP4383855B2 (https=)
AT (1) ATE414100T1 (https=)
AU (1) AU2002326070A1 (https=)
CA (1) CA2451741C (https=)
DE (1) DE60229867D1 (https=)
WO (1) WO2003004517A2 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6521737B1 (en) * 1995-11-10 2003-02-18 Elan Corporation, Plc Peptides which enhance transport across tissues and methods of identifying and using the same
DE60229867D1 (de) * 2001-07-02 2008-12-24 Merrion Res Iii Ltd Zielgerichtete ligande gegen peyer's flecke- und/oder m-zellen
EP1631582A2 (en) * 2003-06-10 2006-03-08 University of Saskatchewan Chimeric adenovirus capsid proteins
AU2012201102B2 (en) * 2004-06-23 2014-05-08 Ferguson, Ian Andrew Agents and methods for early diagnosis and monitoring of Alzheimer's disease and other neurological disorders
DE102005031755B9 (de) * 2005-07-01 2010-04-08 Technische Universität Dresden Salmonella spp. bindende Peptide, dafür kodierende Nukleinsäuren, deren Verwendungen und Verfahren und Kits zur Anreicherung, Immobilisierung und zum Nachweis von Salmonella spp.
WO2007137174A2 (en) * 2006-05-18 2007-11-29 The Ohio State University Research Foundation Compositions and methods for the detection of vulnerable plaque
PL2897620T3 (pl) 2012-09-21 2020-11-02 Intensity Therapeutics, Inc Sposób leczenia nowotworu złośliwego
JP6618892B2 (ja) 2013-04-23 2019-12-11 プレジデント アンド フェローズ オブ ハーバード カレッジ 細菌バイオフィルムの遺伝的リプログラミング
EP3280397A4 (en) * 2015-04-06 2018-08-22 President and Fellows of Harvard College Biosynthetic amyloid-based materials displaying functional protein sequences
WO2017201428A1 (en) 2016-05-19 2017-11-23 President And Fellows Of Harvard College Methods of making gels and film using curli nanofibers
TW201829470A (zh) 2016-10-26 2018-08-16 廖朝暐 用於免疫增強的融合胜肽及使用其增強誘發免疫反應的方法

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR940010862B1 (ko) * 1985-02-05 1994-11-18 씨네겐 바이오로지칼즈, 인코포레이티드 유용한 메탈로프로테이나제 억제제 씨퀀스 재조합 벡터계의 제조를 위한 dna 재조합 방법
IL84167A (en) * 1986-10-24 1991-04-15 Southern Res Inst Oral delivery of bioactive agents to and through the peyer's patch by use of microencapsulation
US5254342A (en) 1991-09-30 1993-10-19 University Of Southern California Compositions and methods for enhanced transepithelial and transendothelial transport or active agents
GB9201139D0 (en) * 1992-01-20 1992-03-11 Connaught Lab Synthetic peptides for a rubella vaccine
AU3937693A (en) 1992-04-10 1993-11-18 Brigham And Women's Hospital Methods and compositions for oral delivery of therapeutic agents
US5534496A (en) 1992-07-07 1996-07-09 University Of Southern California Methods and compositions to enhance epithelial drug transport
AU2159895A (en) * 1994-03-11 1995-09-25 Ariad Pharmaceuticals, Inc. Methods and materials for identifying inhibitors of molecular interactions mediated by sh3 domains
US5831008A (en) * 1994-08-18 1998-11-03 La Jolla Cancer Research Foundation Retinoblastoma protein-interacting zinc finger proteins
US6030613A (en) 1995-01-17 2000-02-29 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of therapeutics
US6086875A (en) 1995-01-17 2000-07-11 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of immunogens
IE80466B1 (en) 1995-11-10 1998-07-29 Elan Corp Plc Peptides which enhance transport across tissues and methods of identifying and using the same
AU705688B2 (en) * 1995-11-10 1999-05-27 Cytogen Corporation Peptides which enhance transport across tissues and methods of identifying and using the same
US6261787B1 (en) 1996-06-03 2001-07-17 Case Western Reserve University Bifunctional molecules for delivery of therapeutics
US6060082A (en) 1997-04-18 2000-05-09 Massachusetts Institute Of Technology Polymerized liposomes targeted to M cells and useful for oral or mucosal drug delivery
JP4129298B2 (ja) * 1997-05-15 2008-08-06 サイトジェン コーポレーション 胃腸管（ｇｉｔ）輸送受容体に結合するランダムペプチド、及び関連した方法
WO2001027154A2 (en) * 1999-09-27 2001-04-19 Mahony Daniel J O Membrane translocating peptide drug delivery system
JP2001245675A (ja) * 1999-12-28 2001-09-11 Kyogo Ito 腫瘍抗原
CN1323825A (zh) * 2000-05-16 2001-11-28 上海博德基因开发有限公司 一种新的多肽——人网格蛋白轻链9和编码这种多肽的多核苷酸
AU2002254161A1 (en) * 2001-03-12 2002-09-24 Montana State University-Bozeman M cell directed vaccines
CA2443644A1 (en) * 2001-04-04 2003-01-16 Elan Corporation, Plc Genetic analysis of peyers's patches and m cells and methods and compositions targeting peyer's patches and m cell receptors
DE60229867D1 (de) * 2001-07-02 2008-12-24 Merrion Res Iii Ltd Zielgerichtete ligande gegen peyer's flecke- und/oder m-zellen

Also Published As

Publication number Publication date
US6916789B2 (en) 2005-07-12
US20050227924A1 (en) 2005-10-13
DE60229867D1 (de) 2008-12-24
CA2451741A1 (en) 2003-01-16
WO2003004517A2 (en) 2003-01-16
EP1432729B1 (en) 2008-11-12
AU2002326070A1 (en) 2003-01-21
US20030096354A1 (en) 2003-05-22
EP1432729A2 (en) 2004-06-30
ATE414100T1 (de) 2008-11-15
WO2003004517A3 (en) 2004-04-29
CA2451741C (en) 2014-02-18
JP2005503782A (ja) 2005-02-10
US7485321B2 (en) 2009-02-03
US20100016549A1 (en) 2010-01-21

Similar Documents

Publication Publication Date Title
US20100016549A1 (en) Peyer's patch and/or m-cell targeting ligands
CN102481341B (zh) 蛋白原及其使用方法
US7563866B2 (en) Modular antigen transporter molecules (MAT molecules) for modulating immune reactions, associated constructs, methods and uses
JP3830525B2 (ja) 組織横断輸送を強化するペプチドとその同定法および使用法
KR101216008B1 (ko) 바이포달 펩타이드 바인더
Siebert et al. Tuftsin-properties and analogs
Kang et al. Identification of a peptide sequence that improves transport of macromolecules across the intestinal mucosal barrier targeting goblet cells
Higgins et al. In vivo phage display to identify M cell-targeting ligands
KR20120125455A (ko) 세포내 타겟 결합용 바이포달 펩타이드 바인더
JP6218175B2 (ja) ヘルパーｔ細胞誘導性ポリペプチドの改変
US20130109616A1 (en) Antimicrobial peptides
JP2005503782A5 (https=)
US10073109B2 (en) Phages of biomarker capture and methods of use
US20130059793A1 (en) Egf receptor mimicking peptides
CN109310729A (zh) 用于改善转染效率的合成化合物
US20050277575A1 (en) Therapeutic compositions and methods for treating diseases that involve angiogenesis
WO2013165262A1 (en) Peptides, constructs and uses therefor
US20250304623A1 (en) Peptides for intracellular delivery
JP4238557B2 (ja) ハイモビリティーグループタンパクと親和性を有するペプチド
WO2013149237A1 (en) Targeting intracellular organelle zip codes with functional homing ligands from cell-internalizing phage combinatorial libraries
CN113557246A (zh) 靶向αvβ3整联蛋白的单域抗体
Mihara et al. Designed Peptide Libraries for Cell Analyzing Microarrays
CN106749536A (zh) 一种黏膜胞转受体gp‑2的高亲和性寡肽及其应用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20050624

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20050624

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20061212

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20080603

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20080822

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20081024

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20081031

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20081216

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20090316

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20090324

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090605

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090804

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090812

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20090915

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20090924

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20121002

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20131002

Year of fee payment: 4

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees